These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12703245)

  • 1. Darbepoetin alfa is improved therapy for chemotherapy-induced anemia.
    ONS News; 2003 Apr; 18(4):5. PubMed ID: 12703245
    [No Abstract]   [Full Text] [Related]  

  • 2. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 3. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R; Smith R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
    Pirker R
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Rossi G; Foote M
    Expert Opin Biol Ther; 2003 Jun; 3(3):501-8. PubMed ID: 12783618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Wauters I
    Expert Opin Pharmacother; 2005 Mar; 6(3):429-40. PubMed ID: 15794734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa: a review of its use in patients with cancer.
    Jung LL; Schwartz RN
    Cancer Pract; 2002; 10(6):327-30. PubMed ID: 12406056
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia.
    Jumbe N; Yao B; Rovetti R; Rossi G; Heatherington AC
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):37-44. PubMed ID: 12435172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of darbepoetin alfa in the management of patients with cancer.
    Gordon MS
    J Support Oncol; 2004; 2(2 Suppl 2):2-3. PubMed ID: 16108417
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia.
    Steensma DP; Sasu BJ; Sloan JA; Tomita DK; Loprinzi CL
    Blood; 2015 Jun; 125(23):3669-71. PubMed ID: 26045598
    [No Abstract]   [Full Text] [Related]  

  • 14. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
    Vansteenkiste J; Wauters I
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
    Glaspy JA
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of anemia with darbepoetin alfa in the radiation oncology setting.
    Finney D; Allison RR
    J Support Oncol; 2005; 3(6 Suppl 4):6-7. PubMed ID: 16355547
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
    Henry DH
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    VanAudenrode M
    J Natl Cancer Inst; 2003 May; 95(10):761-2; author reply 762-3. PubMed ID: 12759400
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.